These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16801939)

  • 21. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent progress in management of advanced prostate cancer.
    Kantoff P
    Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hormone-refractory prostate cancer].
    Alexandre I; Rixe O
    Ann Urol (Paris); 2007 Apr; 41(2):47-55. PubMed ID: 17486912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 26. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of patients with hormone refractory prostate cancer.
    Muthuramalingam SR; Patel K; Protheroe A
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy of hormone-refractory prostate cancer].
    Heidenreich A
    Urologe A; 2005 Dec; 44(12):1481-94; quiz 1495. PubMed ID: 16311709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
    Droz JP; Chaladaj A
    BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer in the late 1990s: hormone refractory disease options.
    Moul JW; Lipo DR
    Urol Nurs; 1999 Jun; 19(2):125-31; quiz 132-3. PubMed ID: 10633763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic options for hormone-refractory prostate cancer].
    Miller K; Börgermann C; Thüroff J; Albers P; Wirth M
    Urologe A; 2006 May; 45(5):580, 582-5. PubMed ID: 16710677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Present status and perspectives in the treatment of hormone-refractory prostate cancer.
    Silvestris N; Leone B; Numico G; Lorusso V; De Lena M
    Oncology; 2005; 69(4):273-82. PubMed ID: 16282706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
    Petrylak DP
    Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Ansari J; Hussain SA; Alhasso A; Mahmood R; Ansari A; Glaholm J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):296-306. PubMed ID: 21426298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Metastatic hormone-sensitive prostate cancer].
    Gravis G; Salem N; Walz J
    Bull Cancer; 2015 Jan; 102(1):57-64. PubMed ID: 25609491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
    Batman E; de Wit R
    Ned Tijdschr Geneeskd; 2005 Oct; 149(44):2442-5. PubMed ID: 16285357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical therapy of prostate cancer. A review.
    Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
    Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.